분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-05-30 12:53:00 , Hit : 934
 Gene therapy drug approval granted to GSK

By Pallab Ghosh
Science correspondent, BBC News

http://www.bbc.com/news/science-environment-36400206?post_id=1006393519444180_1006393559444176#_=_


27 May 2016

From the section Science & Environment

Regulators have given one of the world's largest drug companies approval to sell a new gene therapy.

The treatment is for an illness called ADA-SCID which prevents babies from fighting off everyday infections.

This is the first approval for a genetic therapy granted to a large multinational drug company, GSK.

Commentators say the development marks the beginning of many more genetic medicines from so-called "Big Pharma".

The condition is extremely rare and affects around two dozen babies each year.




Approval of the gene therapy paves the way for the development of treatments for more widespread illnesses such as thalassemia and sickle cell disease.

Hundreds of inherited disorders such as cystic fibrosis, muscular dystrophy and many types of blindness are caused by faulty genes.

Hype

The aim of gene therapies is to cure the disease by introducing healthy copies of the gene into the patient.

And the big advantage of the treatment is that it only needs to be given once and it offers a potentially permanent cure.

The idea first emerged with much hype 30 years ago. At the time, large drug companies such as Novartis and Roche were at the forefront of the technology.

Advocates of gene therapy said it would cure everything but, for 20 years, it cured nothing.

The practicalities of introducing the right gene in the right cells and getting them to stick proved more difficult than first thought.

There were huge setbacks for the technology in the early days.

Difficulties

In 1999, an 18-year-old man Jesse Gelsinger died in a clinical trial of a gene therapy to treat a liver disease. The virus used to transfer the gene into his cells triggered his immune system into overdrive which led to multiple organ failure and brain death.

Three years later, children being treated in Paris for a problem with their immune system developed leukaemia because the healthy gene was inserted too close to a cancer-causing gene which consequently became active.

The setbacks saw large drug companies withdraw from research in the field.

Small biotechnology companies and publicly funded research groups persevered and, in time, many of the early difficulties were overcome.

As well as today's approval of GSK's treatment, which the company calls Strimvelis, in 2012 regulators gave the green light to a gene therapy called Glybera for a pancreatic disorder and another last year called T-Vec for skin cancer.

According to Prof Alan Boyd, who is president of the Faculty of Pharmaceutical Medicine and a pioneer in the development of gene therapy, more approvals are likely to be given in the next few years.

"Most of the hard work has been done by small companies. But as some of these products have come closer to market, Big Pharma has come back in," he says.

Significant step

GSK's Strimvelis marks a starting point for the company to develop its gene therapies. It has research programmes under way for three relatively rare diseases and a programme and another collaboration to use gene therapy to treat cancers.

One of the issues for Big Pharma is how can it make money out of gene therapy. If one treatment cures its customers then is the industry not in danger of putting itself out of business?

GSK's position and those of other drug companies is that it can't afford not to become involved in gene therapy.

If the vision to treat people with one-off treatments that last a long time becomes a reality, any part of the industry that chooses to ignore gene therapy will be in an awful lot of trouble.

So the time is now right for large drug companies companies to become involved in gene therapy again. The question for Big Pharma the how much to charge for a single life-long cure?

Accessible to patients

GSK has not released details of how it will price its new treatment yet but its president of R&D, Patrick Vallance, says that the aim would be to make Strimvelis and any more gene therapies it develops as accessible as possible to as many patients as it can.

"We are absolutely committed to getting the price right," he says. "It's obvious that you can't charge a price that is unaffordable."

No doubt the pricing will work itself out in the long run and as more trials come through, the cost of gene therapy treatments will get less and less.







1067   Foamy 바이러스 벡터를 이용한 유전자 치료  이성욱 2008/02/12 5778
1066   Foot-and-mouth culls could be cut  이성욱 2011/05/11 3155
1065   Former Reginans changing the future of HIV  이성욱 2011/12/28 2256
1064   Fragile X syndrome: Trigger for most common form of intellectual disability and autism uncovered  이성욱 2014/03/05 1770
1063   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 357
1062   Friends connect on a genetic level  이성욱 2011/01/24 2262
1061   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 605
1060   Gene Editing Treats Blood Disease  이성욱 2011/07/16 3017
1059   Gene Study Based on RNA Interference May Lead to New Liver Cancer Therapies  이성욱 2017/08/14 810
1058   Gene Therapy Allows Beethoven Mouse to Hear  이성욱 2015/07/10 874
1057   Gene Therapy Appears to Help Patient With Anemia  이성욱 2010/09/17 2908
  Gene therapy drug approval granted to GSK  이성욱 2016/05/30 934
1055   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 333
1054   Gene Therapy for Controlling HIV Shows Early Promise  이성욱 2014/03/08 1599
1053   Gene Therapy for Immune Disorder Lasts Nine Years, Two New Studies Show  이성욱 2011/08/25 2478
1052   Gene Therapy May Thwart HIV  이성욱 2011/09/23 2055
1051   Gene therapy offers hope for Parkinson's disease  이성욱 2011/03/23 2352
1050   Gene Therapy Shows Promise Against Age-Related Macular Degeneration  이성욱 2011/05/04 2542
1049   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2434
1048   Gene therapy trial on hold  이성욱 2007/08/07 4978

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN